Skip to main content
NGNE
NASDAQ Life Sciences

Neurogene Q3 10-Q: $94.4M Nine-Month Loss, $359.7M Cash Into Q1 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$26
Mkt Cap
$520.296M
52W Low
$15.93
52W High
$43.66
52W Position info
63% above low
Off High info
40% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

NGNE sits 63% above its 52-week low of $15.93.

Summary

Neurogene's Q3 10-Q details a $94.4M nine-month net loss and $359.7M in cash and investments that fund operations into Q1 2029, with $86.2M still available under its ATM and a 548,000-share inducement plan increase.


Key Events · Earnings and Guidance · NGNE

  • Q3 Loss Widens on Trial and CMC Spend

    Net loss was $29.0M for the quarter and $94.4M for nine months, versus $20.95M and $65.6M a year earlier; R&D rose to $23.5M from $17.2M on Embolden trial costs and PPQ manufacturing runs.

  • Cash Funds Operations Into Q1 2029

    Cash, cash equivalents and short-term investments totaled $359.7M at September 30, 2026, after $134.9M net from the July 2026 offering and $31.8M net from ATM sales.

  • ATM Leaves $86.2M of Overhang

    889,054 shares were sold under the $150.0M Leerink Sales Agreement in the first nine months for $31.8M net; $86.2M remains available for future sales.

  • Inducement Plan Raised by 548,000 Shares

    The board approved an increase to the 2025 Inducement Plan's share pool to 1,048,000 shares, effective August 13, 2026.


Analysis · NGNE · Life Sciences

Spending is ramping as Neurogene funds the Embolden registrational trial and process validation for NGN-401, per the full quarterly report behind this morning's 8-K. R&D rose to $23.5M in the quarter from $17.2M a year ago, and the nine-month net loss widened to $94.4M from $65.6M. The balance sheet is the offset: $359.7M of cash and short-term investments after the July offering and ATM sales, enough to fund operations into the first quarter of 2029, past the second-half 2027 Embolden topline. Dilution is the cost — shares outstanding grew to 20.7M from 15.5M at year-end, and $86.2M remains available under the ATM, a standing overhang. The only new governance item is a 548,000-share increase to the 2025 Inducement Plan.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NGNE was trading at $26.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $520.3M. The 52-week trading range was $15.93 to $43.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NGNE - Latest Insights

NGNE
Nov 09, 2026, 8:19 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.31
Real-time Price: $25.39 info
Change: +$0.080 (+0.32%) info
Market Cap: $525.596M info
NGNE
Aug 11, 2026, 4:57 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.80
Real-time Price: $25.39 info
Change: -$10.41 (-29%) info
Market Cap: $525.596M info
NGNE
Aug 11, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.21
Real-time Price: $25.39 info
Change: -$10.82 (-30%) info
Market Cap: $525.596M info
NGNE
Aug 11, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $36.21
Real-time Price: $25.39 info
Change: -$10.82 (-30%) info
Market Cap: $525.596M info
NGNE
Jul 02, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $31.97
Real-time Price: $25.39 info
Change: -$6.58 (-21%) info
Market Cap: $525.596M info